Ask AI
ProCE Banner Series

Global Perspectives on New Data in Type 2 Diabetes — Congress-to-Clinic Insights From ADA and EASD 2025

Experience a high-impact, CME-certified webinar where leading global diabetes experts distill the most clinically relevant data from ADA 2025 and EASD 2025. This interactive congress-to-clinic session translates breakthrough findings in type 2 diabetes into actionable insights for real-world practice. Engage with cutting-edge science and elevate patient care through expert-led discussion and peer exchange.

  AMA
Who Should Attend

This activity is intended for endocrinologists, diabetologists, and other HCPs who manage patients with T2D across the globe.

All Events

Global Perspectives on New Data in Type 2 Diabetes — Congress-to-Clinic Insights From ADA and EASD 2025

Upcoming Events

October

01

2025

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Topics

Diabetes

Additional Info

Date & Times
Wednesday, October 1, 2025
8:00 AM - 9:00 AM EST (Eastern Standard Time)
2:00 PM - 3:00 PM CEST (Central European Summer Time)
8:00 PM - 9:00 PM CST (China Standard Time)

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This educational activity aims to improve learners’ knowledge of and competence in the timely application of emerging data in type 2 diabetes to patient care.

Target Audience
This activity is intended for endocrinologists, diabetologists, and other HCPs who manage patients with T2D across the globe.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise the safety, efficacy, and adherence profiles of new and emerging therapies for individuals with T2D

  • Incorporate recent safety and efficacy evidence into strategies that prioritize weight loss as part of comprehensive T2D management

  • Evaluate the comparative extraglycemic efficacy of new and emerging T2D agents and their potential role in the management of T2D

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.com to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC

Supporters

Supported by an educational grant from Lilly.

Lilly

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191